Nitrofurantoin ve Fosfomisinin İdrar Yolu ... - Yeni Tıp Dergisi

%97, ampisiline % 29, norfloksasine % 67, ampisilin-sulbaktama
%52, trimetoprim-sulfametoksa-
iltir 24 . Bizim
amoksisilin/klavulanik asit,
trimetoprim-sulfametoksazol ve nitrofurantoin
ülkemizdeki nurken,
-tibiyotiklerin du
25 80 GSBL pozitif E. coli
birinin fosfomisine dirençli
direncin %66, trimetoprim-sulfametoksazol
16 fosfomisin du -
GSBL pozitif
fark bulamazken; gentamisin, nitrofurantoin,
amoksisilin-klavulanik asit, trimetoprimsulfametoksazol,
ampisilin ve levofloksasine
GSBL pozitif olan izolatlarda daha fazla direncin
ve ark. 26 GSBL
negatiflerde fosfomisin direnci saptamazken, pozitiflerin
%2’sinde direnç .
da
tir
21,22 . Bizim -
direnç -
Pullukçu ve ark. 21 yatan hastalardan soyutlanan
kökenlerde nitrofurantoin direncini poliklinik
bul Bizim
k yatan hastalardan elde edilen izolatlarda
siprofloksasin, sefepim ve trimetoprimsulfametoksazol
direnci daha fazla bulunurken,
nitrofurantoin
Sonuç olarak; E. coli n
ampirik tedavisinde fosfomisin ve nitrofurantoinin
REFERANSLAR
1. In: Willke Topçu A,
, editors.
Mikrobiyolojisi. 2008. s.1487-1506.
2. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Urinary Tract
Infection Study Group: Risk factors for ciprofloxacin resistance among
Escherichia coli strains isolated from community-acquired urinary tract
infections in Turkey. J Antimicrob Chemother 2005;56(5):914-8.
3. Keskin SK, Tokuç
R. Son d risinde idrar kültürlerinden iz
ge . Türk Üroloji Dergisi 2009;35(3):
201-9.
4. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett
JE, Dolin R, editors. 5th ed. Principles and Practice of Infectious Disease.
Churcill Livingstone: Philadelphia; 2000. p.773-800.
5. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of
Escherichia coli from community-acquired urinary tract infections in Europe:
the ECO·SENS study revisited. Int J Antimicrob Agents 2012;39(1):45-51.
6. Sanders CC, Sanders WE. Beta-lactam resistance in gram negative
bacteria; Global trends and clinical impact. Clin Infect Dis 1992;15(5):824-
83.
7. Steward CD, Rasheed JK, Hubert SK, Biddle JW, Raney PM,
Anderson GJ, et al. Characterization of clinical isolates of Klebsiella
pneumoniae from 19 laboratories using the National committee for clinical
laboratory standards extended-spectrum–lactamase detection methods.
JCM 2001;39(8):2864-72.
8. Procop GW, Tuohy MJ, Wilson DA, Williams D, Hadziyannis E, Hall
GS. Cross-class resistance to non betalactam antimicrobials in extended
spectrum beta-lactamase producing Klebsiella pneumoniae. Am J Clin
Pathol 2003;120(2):265-67.
9. istem antiseptikleri. In: Willke-Topçu A, Söyletir
, editors.
2008. s.377-87.
10. Falagas ME, Giannapoulou KP, Kokolakis GN, Rafailidis PI.
Fosfomycin: Use beyond uninary tract and gastrointestinal infections. Clin
Infect Dis 2008;46(7):1069-77.
11. Clinical and Laboratory Standarts Institute. Performance Standarts
for Antimicrobial Susceptibility Testing; Tweenty-First Informational
Supplement. CLSI document (M100-S21), CLSI, Wayne PA (2011).
12. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study
in Europe and Brazil on clinical aspects and Antimicrobial Resistance
Epidemiology in Females with Cystitis (ARESC): implications for empiric
therapy. Eur Urol 2008;54(5):1164-75.
13. Alós JI, Serrano MG, Gómez-Garcés JL, Perianes J. Antibiotic
resistance of Escherichia coli from community-acquired urinary tract
infections in relation to demographic and clinical data. Clin Microbiol Infect
2005;11(3):199-203.
14.
-7.
15. . In-vitro susceptibility of
clinical isolates of Escherichia coli to fosfomycin trometamol and other
antibiotics. ANKEM Derg 2005;19(2):77-9.
16.
-Vitro
-102.
17. Deveci Ö, Yula E, Toka-Özer T, Tekin A. Üriner sistem
Escherichia coli
trometamolün -
2011;38(3):298-300.
18.
Yolu infeksiyonu Etkeni Olan Escherichia coli
Derg 2008;22(2):81-4.
19.
-KEM Derg 2009;
23(4):172-6.
20. -
Escherichia coli
198-201.
21. Pull
Nitrofurantoinin idrar kültürlerinden soyutlanan Escherichia coli in
vitro -200.
22. n Vitro
Escherichia coli Strains
Isolated from Urine Cultures. The New Journal of Medicine 2012;29(2):88-
91.
23. Aykut Arca E, Karabiber N. Short communication: comparison of
susceptibilities of Escherichia coli urinary tract isolates against fosfomycin
tromethamine and different antibiotics. Mikrobiyol Bul 2007;41(1):115-9.
24.
Escherichia coli, Klebsiella ve Enterokok cinsi bakterilerde fosfomisin
-22.
25.
Activity of Fosfomycin Against Extended Spectrum--Lactamase (ESBL)
Producing Escherichia coli and Klebsiella pneumoniae Strains. Turk J
Immunol 2008;13:1-4.
26. , Ozyurt M, Baylan O, Bektöre B, Ardiç N, Ceylan S, et al.
In vitro activity of fosfomycin trometamol in the treatment of Escherichia
coli related uncomplicated urinary tract infections. Mikrobiyol Bul 2009;43
(4):645-9.
78